Genetic control of mammalian cells with synthetic RNA regulatory systems
View Patent ↗The present application relates to nucleic acids that encode a RNA switch responsive to a ligand that can control the expression of a gene product that affects the cell fate determination of a mammalian cell are provided. In some embodiments, the system can be used to control the proliferation or activation of mammalian cells in response to a ligand that can be provided exogenously to the mammalian cell or can be produced by the mammalian cell. The system can be used to promote the growth or proliferation of human T cells in response to an exogenous ligand applied to the cells. In one embodiment, the system detects the ligand through a RNA aptamer that modulates expression of a gene product through activation or inactivation of a ribozyme that modulates expression of the gene product.
1. A nucleic acid that encodes: (a) a gene product that affects a cell fate decision of a lymphocyte, and (b) two or more copies of an RNA switch nucleic acid domain, each comprising a sensor domain and an actuator domain, wherein the sensor domain is configured to bind to theophylline and the actuator domain modulates expression of the gene product; wherein binding of theophylline to the sensor domain modulates the functional activity of the actuator domain modulating the expression of the gene product, thereby providing control over basal expression level of the gene product, wherein the sensor domain is encoded by a sequence comprising L2bulge9 (SEQ ID NO: 28).
2. The nucleic acid of claim 1 , wherein the nucleic acid encodes three or more copies of the RNA switch nucleic acid domain, and wherein the sensor domains of each RNA switch nucleic acid domain bind to theophylline independently.
3. The nucleic acid of claim 1 , wherein the cell fate decision is T-cell activation, proliferation, apoptosis or differentiation.
4. The nucleic acid of claim 1 , wherein the actuator domain is a ribozyme.
5. The nucleic acid of claim 4 , wherein the ribozyme is a hammerhead ribozyme.
6. The nucleic acid of claim 4 , wherein the ribozyme is located in the 3′ untranslated region of the gene product.
7. The nucleic acid of claim 6 , wherein the ribozyme cleaves the 3′ untranslated region in the absence of theophylline.
8. The nucleic acid of claim 6 , wherein the ribozyme cleaves the 3′ untranslated region in the presence of theophylline.
9. The nucleic acid of claim 1 , wherein the gene product is a cytokine receptor, or a cytokine-cytokine receptor fusion protein.
10. The nucleic acid of claim 1 , wherein the gene product is a cytokine.
11. The nucleic acid of claim 10 , wherein the cytokine is IL-2, IL-4, IL-7, IL-9 or IL-15.
12. The nucleic acid of claim 1 , wherein the nucleic acid further encodes a fluorescent protein.
13. The nucleic acid of claim 1 , wherein the nucleic acid further encodes a safety protein that kills a host cell comprising said system, in the presence of a drug or a prodrug.
14. The nucleic acid of claim 1 , wherein the gene product is a T-cell receptor targeting a tumor-associated antigen.
15. The nucleic acid of claim 14 , wherein the T-cell receptor targeting the tumor-associated antigen is patient-derived, or is synthetic.
16. The nucleic acid of claim 13 , wherein the safety protein is a thymidylate kinase, or CD20.
17. A lymphocyte comprising the nucleic acid of claim 1 .
18. The nucleic acid of claim 1 , wherein the nucleic acid that encodes the gene product is a multi-gene transgene.
19. The lymphocyte of claim 17 , further comprising a nucleic acid encoding a receptor for a tumor-associated antigen.
20. A method of affecting the proliferation or activation of a T cell in a mammal, the method comprising: providing to the mammal, a mammalian cell comprising the nucleic acid of claim 1 .
21. The method of claim 20 , further comprising providing to the mammal an effective amount of theophylline to affect proliferation or activation of the T cell.